Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

A new generation of GLP-1 drugs promising fast results continues to rock the weight loss industry, which has emphasized ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings, but cut its guidance ...

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...